AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23875707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultradeep sequencing (UDS)
Number of subjects: 304
Study 23875707 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant non-R5 results by UDS and ESTA
Number of subjects: 304
Study 21957032 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/low-glycaemic index (HP/LGI) diet
Number of subjects: 24
Study 21957032 — intervention group
Group type: COMPARATOR
Intervention: Low-protein/low-glycaemic index (LP/LGI) diet
Number of subjects: 24
Study 19632963 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐Scan insole plantar pressure system
Number of subjects: 15
Study 17910651 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal (decreasing steroid doses stopping at day 7 post-transplant)
Number of subjects: 23
Study 17910651 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal
Number of subjects: 23
Study 17910651 — intervention group
Group type: COMPARATOR
Intervention: Steroid-based control group (CsA, AZT)
Number of subjects: 23
Study 17910651 — intervention group
Group type: COMPARATOR
Intervention: Steroid-based control group
Number of subjects: 23
Study 17910651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 23
Study 15142000 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised resistance training (SUP)
Number of subjects: 42
Study 15142000 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised resistance training (UNSUP)
Number of subjects: 42
Study 11549952 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 115
Study 11549952 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (C)
Number of subjects: 115
Study 9513957 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (steroid + local anaesthetic)
Number of subjects: 103
Study 9513957 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment (spine-decompressing position, traction, therapeutic exercises)
Number of subjects: 103
Study 8400091 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (5 micrograms/kg)
Number of subjects: 43
Study 3020754 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP + DVA
Number of subjects: 116
Study 3020754 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP + VP16
Number of subjects: 116
Study 3020754 — intervention group
Group type: COMPARATOR
Intervention: DXR + CTX
Number of subjects: 116
Study 3020754 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 116
Study 3020754 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 116
Study 31030774 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophobic POD F GF IOL
Number of subjects: 25
Study 29773818 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-malarial compounds in EIA
Number of subjects: 44
Study 29773818 — intervention group
Group type: EXPERIMENTAL
Intervention: pIC50 for 11 different compounds in EIA
Number of subjects: 44
Study 26415743 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention (PI)
Number of subjects: 113
Study 26415743 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 113
Study 23949133 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard right-thread interference screw for femoral graft fixation
Number of subjects: 107
Study 22234626 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy (HT)
Number of subjects: 61
Study 22234626 — intervention group
Group type: COMPARATOR
Intervention: No hysterectomy (HT)
Number of subjects: 61
Study 21211323 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) administered for 1 - 3 cycles before radical hysterectomy and lymphadenectomy.
Number of subjects: 139
Study 21211323 — intervention group
Group type: COMPARATOR
Intervention: Director operation (DOR) without prior chemotherapy, radical hysterectomy performed directly after diagnosis.
Number of subjects: 139
Study 18394771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD; 1100 ppmF) + 3 applications of acidulated phosphate fluoride (APF; 12,300 ppmF)
Number of subjects: 5
Study 18394771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (FD; 1100 ppmF) + 4 applications of acidulated phosphate fluoride (APF; 12,300 ppmF)
Number of subjects: 5
Study 18394771 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice (FD; 1100 ppmF)
Number of subjects: 5
Study 16009171 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 180 mg/day orally for three cycles of 28 days
Number of subjects: 40
Study 16009171 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (3 tablets/day orally)
Number of subjects: 40
Study 16009171 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 40
Study 16009171 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 14563546 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 14
Study 14563546 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 14
Study 10392680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 24
Study 10392680 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 24
Study 10392680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8658378 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (5-100 pmol/min)
Number of subjects: 6
Study 8658378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (5-50 micrograms/kg/min)
Number of subjects: 6
Study 8316387 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 7
Study 8316387 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 7
Study 2878597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol 400 mg
Number of subjects: 229
Study 2878597 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 229
Study 31759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Single ketamine infusion
Number of subjects: 37
Study 31759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated ketamine infusions (six infusions thrice-weekly over 2 weeks)
Number of subjects: 37
Study 31759333 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance infusions (four further infusions once-weekly)
Number of subjects: 37
Study 30175606 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid
Number of subjects: 37
Study 30175606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (low molecular weight)
Number of subjects: 37
Study 30175606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (high molecular weight)
Number of subjects: 37
Study 30175606 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (third administration)
Number of subjects: 37
Study 27085606 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 37
Study 27085606 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 37
Study 27085606 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state connectivity analysis
Number of subjects: 37
Study 24173681 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 45
Study 21182551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gum (2 mg or 4 mg)
Number of subjects: 103
Study 21182551 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 103
Study 21182551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gum (compliant use ≥9 pieces/day)
Number of subjects: 103
Study 21182551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gum (non-compliant use <9 pieces/day)
Number of subjects: 103
Study 21182551 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (2 mg or 4 mg)
Number of subjects: 103
Study 19403553 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made semi-rigid insole
Number of subjects: 42
Study 19403553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-made simple soft insole
Number of subjects: 42
Study 19403553 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison group with different insoles)
Number of subjects: 42
Study 17446413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Number of subjects: 18
Study 17446413 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Number of subjects: 18
Study 15213282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 7
Study 15213282 — intervention group
Group type: COMPARATOR
Intervention: No IDPN (Control)
Number of subjects: 7
Study 11245710 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 18
Study 11245710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9143758 — intervention group
Group type: EXPERIMENTAL
Intervention: High-compliance balloons
Number of subjects: 800
Study 9143758 — intervention group
Group type: COMPARATOR
Intervention: Low-compliance balloons
Number of subjects: 800
Study 8130921 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches (delivering 15 mg over 16 hours) with low-intensity support
Number of subjects: 248
Study 8130921 — intervention group
Group type: COMPARATOR
Intervention: Placebo with low-intensity support
Number of subjects: 248
Study 3654238 — intervention group
Group type: EXPERIMENTAL
Intervention: UAB program (special intervention)
Number of subjects: 0
Study 3654238 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 31650529 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iliopsoas plane block (5 mL lidocaine 18 mg/mL with epinephrine)
Number of subjects: 20
Study 31650529 — intervention group
Group type: COMPARATOR
Intervention: Sham iliopsoas plane block (saline)
Number of subjects: 20
Study 31650529 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iliopsoas plane block
Number of subjects: 20
Study 31650529 — intervention group
Group type: COMPARATOR
Intervention: Sham iliopsoas plane block
Number of subjects: 20
Study 29313751 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose-ZW (28 g)
Number of subjects: 99
Study 29313751 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose-ZW (14 g)
Number of subjects: 99
Study 29313751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 28088231 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (maximum of 1800 mg/day for 5 weeks)
Number of subjects: 134
Study 28088231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 25325608 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 264
Study 25325608 — intervention group
Group type: COMPARATOR
Intervention: Diabetes and support education (DSE)
Number of subjects: 264
Study 25325608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (both ILI and DSE)
Number of subjects: 264
Study 24289111 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamplay parenting intervention
Number of subjects: 26
Study 24289111 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 20663456 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm blood glucose testing (PBGT)
Number of subjects: 0
Study 20663456 — intervention group
Group type: COMPARATOR
Intervention: Traditional fingertip blood glucose testing (FBGT)
Number of subjects: 0
Study 17632023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol (2mg/day)
Number of subjects: 11
Study 17632023 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg, twice daily)
Number of subjects: 11
Study 17632023 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulobuterol
Number of subjects: 11
Study 17632023 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 11
Study 16893984 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg PS antigen
Number of subjects: 281
Study 16893984 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg PS vaccinating dose
Number of subjects: 281
Study 16893984 — intervention group
Group type: COMPARATOR
Intervention: Baseline samples
Number of subjects: 281
Study 16893984 — intervention group
Group type: COMPARATOR
Intervention: Days 2 to 3
Number of subjects: 281
Study 12925477 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 72
Study 12925477 — intervention group
Group type: COMPARATOR
Intervention: Classic LMA
Number of subjects: 72
Study 10773644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 153
Study 10773644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 9009369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% mitomycin C eye drops, four times daily for two weeks or longer after surgery
Number of subjects: 66
Study 9009369 — intervention group
Group type: COMPARATOR
Intervention: Surgery only (no mitomycin C)
Number of subjects: 66
Study 9009369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% mitomycin C eye drops
Number of subjects: 66
Study 2058822 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative autologous deposit
Number of subjects: 64
Study 2058822 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hemodilution
Number of subjects: 64
Study 2058822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra- and postoperative autotransfusion
Number of subjects: 64
Study 2058822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 12265805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylon T IUD
Number of subjects: 0
Study 12265805 — intervention group
Group type: COMPARATOR
Intervention: Copper T 200
Number of subjects: 0
Study 30819458 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management program (IY TCM)
Number of subjects: 0
Study 28893755 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based menu planning intervention with training and follow-up support
Number of subjects: 54
Study 28893755 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 54
Study 25642812 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac sodium hydrate (NSAID)
Number of subjects: 28
Study 25642812 — intervention group
Group type: COMPARATOR
Intervention: Flavin adenine dinucleotide sodium (Control)
Number of subjects: 28
Study 25189175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium lactate solution (HSL) - 5 ml/kg/BW in 15 minutes followed by 1 ml/kg/BW/h for 12 hours
Number of subjects: 50
Study 25189175 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate (RL) - 20 ml/kg/BW in 15 minutes followed by decreasing doses of 10, 7, 5, and 3 ml/kg BW/h for 12 hours
Number of subjects: 50
Study 25189175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic sodium lactate solution (HSL)
Number of subjects: 50
Study 25189175 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate (RL)
Number of subjects: 50
Study 22005922 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction catheter aspiration
Number of subjects: 272
Study 22005922 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps biopsy
Number of subjects: 272
Study 22005922 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both techniques
Number of subjects: 272
Study 20141250 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention training
Number of subjects: 0
Study 20141250 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 17555932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 208
Study 17555932 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak gradient 80 mm Hg or greater
Number of subjects: 208
Study 17555932 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve area less than or equal to 0.75 cm(2)
Number of subjects: 208
Study 17555932 — intervention group
Group type: EXPERIMENTAL
Intervention: Large left ventricular outflow tract dimension
Number of subjects: 208
Study 17555932 — intervention group
Group type: COMPARATOR
Intervention: Normal left ventricular outflow tract dimension
Number of subjects: 208
Study 16359401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi polysaccharide (PS) vaccine
Number of subjects: 200000
Study 16359401 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200000
Study 11953977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide, pulse methylprednisolone, or the combination of both
Number of subjects: 145
Study 11953977 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional immunosuppressive therapy
Number of subjects: 145
Study 11953977 — intervention group
Group type: COMPARATOR
Intervention: Complete response
Number of subjects: 145
Study 11953977 — intervention group
Group type: COMPARATOR
Intervention: Partial response
Number of subjects: 145
Study 10215731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 25 mg
Number of subjects: 577
Study 10215731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 577
Study 10215731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 125 mg
Number of subjects: 577
Study 10215731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 7824101 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 18
Study 7824101 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 18
Study 7824101 — intervention group
Group type: EXPERIMENTAL
Intervention: L/R HF ratios
Number of subjects: 18
Study 7824101 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI volumetric studies
Number of subjects: 18
Study 7824101 — intervention group
Group type: EXPERIMENTAL
Intervention: HF volume ratios and T2 MRI
Number of subjects: 18
Study 7824101 — intervention group
Group type: EXPERIMENTAL
Intervention: hippocampal volume and cerebral metabolic rate of glucose asymmetry index
Number of subjects: 18
Study 7824101 — intervention group
Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 18
Study 2089142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubidecarenone (CoQ10)
Number of subjects: 44
Study 507480 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 25 ug/kg
Number of subjects: 8
Study 507480 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 50 ug/kg
Number of subjects: 8
Study 507480 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 100 ug/kg
Number of subjects: 8
Study 507480 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 50 ug/kg tid
Number of subjects: 8
Study 507480 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 75 or 100 ug/kg tid
Number of subjects: 8
Study 507480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31741317 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractors sharing target color context
Number of subjects: 0
Study 31741317 — intervention group
Group type: EXPERIMENTAL
Intervention: Distractors sharing target orientation context
Number of subjects: 0
Study 30893220 — intervention group
Group type: EXPERIMENTAL
Intervention: CNB
Number of subjects: 110
Study 30893220 — intervention group
Group type: EXPERIMENTAL
Intervention: ANB
Number of subjects: 110
Study 30893220 — intervention group
Group type: COMPARATOR
Intervention: FHB
Number of subjects: 110
Study 27492336 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day voice rest
Number of subjects: 31
Study 27492336 — intervention group
Group type: COMPARATOR
Intervention: 7-day voice rest
Number of subjects: 31
Study 24368514 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 132
Study 24368514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 22804353 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive blood transfusion
Number of subjects: 237
Study 22804353 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 237
Study 23845131 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement Initiative (QI)
Number of subjects: 6000
Study 23845131 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 6000
Study 19621834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy with exposure and response prevention
Number of subjects: 0
Study 19621834 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 0
Study 19621834 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation of SSRI with atypical antipsychotic
Number of subjects: 0
Study 19621834 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 0
Study 19621834 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for comorbid depression and suicidal ideation
Number of subjects: 0
Study 17214404 — intervention group
Group type: EXPERIMENTAL
Intervention: Random whole-body vibration (5 series of 60 seconds each)
Number of subjects: 28
Study 17214404 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest period)
Number of subjects: 28
Study 12634293 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise + HRT (n = 20)
Number of subjects: 94
Study 12634293 — intervention group
Group type: EXPERIMENTAL
Intervention: exercise (n = 24)
Number of subjects: 94
Study 12634293 — intervention group
Group type: COMPARATOR
Intervention: HRT (n = 22)
Number of subjects: 94
Study 12634293 — intervention group
Group type: COMPARATOR
Intervention: control (n = 28)
Number of subjects: 94
Study 10634401 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake
Number of subjects: 1552
Study 10634401 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1552
Study 10634401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake
Number of subjects: 1552
Study 10634401 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 1552